Drug Type CRISPR/Cas |
Synonyms CasRx-based RNA targeting therapy (University of Texas at Dallas) |
Target |
Mechanism NAB2 inhibitors(NGFI-A binding protein 2 inhibitors), STAT6 inhibitors(signal transducer and activator of transcription 6 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | 02 May 2023 |